可穿戴/移动设备在隐匿性心房颤动管理中的应用进展和挑战

doi:10.12114/j.issn.1007-9572.2023.0755

中国全科医学 ›› 2024, Vol. 27 ›› Issue (30): 3835-3840.DOI: 10.12114/j.issn.1007-9572.2023.0755

• 综述与专论 • 上一篇

可穿戴/移动设备在隐匿性心房颤动管理中的应用进展和挑战

高晨曦¹, 陈德芳², 陈清勇², 沈灿¹^,^*(), 廖晓阳¹^,^*()

1．610041　四川省成都市，四川大学华西医院全科医学中心
2．610041　四川省成都市，四川大学华西医院心脏内科

收稿日期:2023-12-06 修回日期:2024-03-04 出版日期:2024-10-20 发布日期:2024-07-09
通讯作者: 沈灿, 廖晓阳
作者贡献：
高晨曦负责确定论文选题、撰写及修改，文章的质量控制及核查，并对文章整体负责；陈德芳负责文献检索、筛选和去重；陈清勇负责文献数据分析；沈灿和廖晓阳负责论文修改，文章结构总体把控，确定终稿，并对文章整体负责。
基金资助:
四川大学华西医院临床研究1.3.5孵化项目(2019HXFH059)

Updated Progress and Challenges in the Application of Wearable/Mobile Devices in the Management of Silent Atrial Fibrillation

GAO Chenxi¹, CHEN Defang², CHEN Qingyong², SHEN Can¹^,^*(), LIAO Xiaoyang¹^,^*()

1. Center for General Practice, West China Hospital of Sichuan University, Chengdu 610041, China
2. Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, China

Received:2023-12-06 Revised:2024-03-04 Published:2024-10-20 Online:2024-07-09
Contact: SHEN Can, LIAO Xiaoyang

分享到

摘要/Abstract

摘要： 心房颤动是常见的心律失常之一，可引起心力衰竭、脑卒中等严重并发症，导致患者致死率、致残率增加。隐匿性心房颤动无明显临床症状，且发作不规律，漏诊率高，无法及时规范诊疗，更易导致不良临床结局。近期临床研究表明可穿戴设备在隐匿性心房颤动的筛查和管理中有显著优势。本文基于国内外近年相关文献复习，对可穿戴设备在隐匿性心房颤动筛查与管理中的最新研究现状、临床结局、成本效益、应用挑战及前景进行综述，以期为其在隐匿性心房颤动管理中的进一步应用提供更多循证证据支持。

关键词: 可穿戴电子设备, 可移动, 隐匿性心房颤动, 管理, 进展

Abstract:

Atrial fibrillation (AF) is among the most prevalent types of arrhythmia, leading to severe complications such as heart failure and stroke, thus increasing rates of mortality and disability. Silent AF, which lacks clinical symptoms and has irregular onset, tends to have a low diagnosis rate and often experiences delays in receiving standardized treatments, resulting in negative clinical outcomes. Recent clinical studies highlight the significant benefits of wearable devices in the screening and management of silent AF. In this article, we review the clinical outcomes, cost-effectiveness, challenges and future application prospects of wearable devices in the detection and management of silent AF based on relevant domestic and international literature of recent years to provide more evidence-based support for its further applications.

Key words: Wearable electronic devices, Mobile, Silent atrial fibrillation, Management, Progress

中图分类号:

R R197.38

高晨曦,陈德芳,陈清勇,等. 可穿戴/移动设备在隐匿性心房颤动管理中的应用进展和挑战[J]. 中国全科医学, 2024, 27(30): 3835-3840. DOI: 10.12114/j.issn.1007-9572.2023.0755.
GAO Chenxi,CHEN Defang,CHEN Qingyong, et al. Updated Progress and Challenges in the Application of Wearable/Mobile Devices in the Management of Silent Atrial Fibrillation[J]. Chinese General Practice, 2024, 27(30): 3835-3840. DOI: 10.12114/j.issn.1007-9572.2023.0755.

参考文献 32

[1]	ELLIOTT A D, MIDDELDORP M E, VAN GELDER I C，et al. Epidemiology and modifiable risk factors for atrial fibrillation[J]. Nat Rev Cardiol，2023,20(6):404-417. DOI：10.1038/s41569-022-00820-8.
[2]	中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动：目前的认识和治疗建议（2021）[J]. 中华心律失常学杂志，2022,26(1):15-88. DOI：10.3760/cma.j.cn113859-20211224-00264.
[3]	US Preventive Services Task Force, DAVIDSON K W, ARRY M J，et al. Screening for atrial fibrillation：US preventive services task force recommendation statement[J]. JAMA，2022,327(4):60-367. DOI：10.1001/jama.2021.23732.
[4]	KAHWATI L C, ASHER G N, KADRO Z O，et al. Screening for atrial fibrillation：updated evidence report and systematic review for the US preventive services task force[J]. JAMA，2022,327(4):368-383. DOI：10.1001/jama.2021.21811.
[5]	TURAKHIA M P, GUO J D, KESHISHIAN A，et al. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States[J]. Clin Cardiol，2023,46(5):484-493. DOI：10.1002/clc.23983.
[6]	中国心血管健康与疾病报告编写组. 《中国心血管健康与疾病报告2022》概要[J]. 中国介入心脏病学杂志，2023,31(7):485-508. DOI：10.3969/j.issn.1004-8812.2023.07.002.
[7]	DU X, GUO L Z, XIA S J，et al. Atrial fibrillation prevalence，awareness and management in a nationwide survey of adults in China[J]. Heart，2021,107(7):535-541. DOI：10.1136/heartjnl-2020-317915.
[8]	US Preventive Services Task Force, CURRY S J, KRIST A H，et al. Screening for atrial fibrillation with electrocardiography：US preventive services task force recommendation statement[J]. JAMA，2018,320(5):478-484. DOI：10.1001/jama.2018.10321.
[9]	LIP G Y H, FAUCHIER L, FREEDMAN S B，et al. Atrial fibrillation[J]. Nat Rev Dis Primers，2016,2:16016. DOI：10.1038/nrdp.2016.16.
[10]	DILAVERIS P E, KENNEDY H L. Silent atrial fibrillation：epidemiology，diagnosis，and clinical impact[J]. Clin Cardiol，2017,40(6):413-418. DOI：10.1002/clc.22667.
[11]	SIONTIS K C, GERSH B J, KILLIAN J M，et al. Typical，atypical，and asymptomatic presentations of new-onset atrial fibrillation in the community：characteristics and prognostic implications[J]. Heart Rhythm，2016,13(7):1418-1424. DOI：10.1016/j.hrthm.2016.03.003.
[12]	HINDRICKS G, POTPARA T, DAGRES N，et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery （EACTS）：the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology （ESC） developed with the special contribution of the European Heart Rhythm Association （EHRA） of the ESC[J]. Eur Heart J，2021,42(5):373-498. DOI：10.1093/eurheartj/ehaa612.
[13]	高晨曦，陈清勇. 可穿戴设备用于心房颤动筛查的有效性系统评价[J]. 中华全科医学，2022,20(7):1230-1234. DOI：10.16766/j.cnki.issn.1674-4152.002565.
[14]	ANDRADE J G, AGUILAR M, ATZEMA C，et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation[J]. Can J Cardiol，2020,36(12):1847-1948. DOI：10.1016/j.cjca.2020.09.001.
[15]	Writing Group Members, JANUARY C T, WANN L S，et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Heart Rhythm，2019,16(8):e66-93. DOI：10.1016/j.hrthm.2019.01.024.
[16]	KAASENBROOD F, HOLLANDER M, DE BRUIJN S H，et al. Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice：a cluster randomised controlled trial[J]. Br J Gen Pract，2020,70(695):e427-433. DOI：10.3399/bjgp20X708161.
[17]	UITTENBOGAART S B, VERBIEST-VAN GURP N, LUCASSEN W A M，et al. Opportunistic screening versus usual care for detection of atrial fibrillation in primary care：cluster randomised controlled trial[J]. BMJ，2020,370:m3208. DOI：10.1136/bmj.m3208.
[18]	LUBITZ S A, ATLAS S J, ASHBURNER J M，et al. Screening for atrial fibrillation in older adults at primary care visits：vital-AF randomized controlled trial[J]. Circulation，2022,145(13):946-954. DOI：10.1161/CIRCULATIONAHA.121.057014.
[19]	GUO Y T, LANE D A, WANG L M，et al. Mobile health technology to improve care for patients with atrial fibrillation[J]. J Am Coll Cardiol，2020,75(13):1523-1534. DOI：10.1016/j.jacc.2020.01.052.
[20]	SVENNBERG E, FRIBERG L, FRYKMAN V，et al. Clinical outcomes in systematic screening for atrial fibrillation （STROKESTOP）：a multicentre，parallel group，unmasked，randomised controlled trial[J]. Lancet，2021,398(0310):1498-1506. DOI：10.1016/S0140-6736(21)01637-8.
[21]	HALCOX J P J, WAREHAM K, CARDEW A，et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation：the REHEARSE-AF study[J]. Circulation，2017,136(19):1784-1794. DOI：10.1161/CIRCULATIONAHA.117.030583.
[22]	ELLINS E A, WAREHAM K, HARRIS D E，et al. Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation：the REHEARSE-AF study[J]. Eur Heart J Open，2023,3(3):oead047. DOI：10.1093/ehjopen/oead047.
[23]	GLADSTONE D J, WACHTER R, SCHMALSTIEG-BAHR K，et al. Screening for atrial fibrillation in the older population：a randomized clinical trial[J]. JAMA Cardiol，2021,6(5):558-567. DOI：10.1001/jamacardio.2021.0038.
[24]	WU S S, XIE S, XU Y J，et al. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation[J]. J Clin Nurs，2019,28(9/10):1839-1846. DOI：10.1111/jocn.14797.
[25]	陈汝明，史展，卢晓英，等. 智能手表对心房颤动患者抗凝药依从性的影响[J]. 中华心律失常学杂志，2022,26(3):272-276. DOI：10.3760/cma.j.cn113859-20220316-00050.
[26]	GUO Y T, GUO J, SHI X M，et al. Mobile health technology-supported atrial fibrillation screening and integrated care：a report from the mAFA-Ⅱ trial Long-term Extension Cohort[J]. Eur J Intern Med，2020,82:105-111. DOI：10.1016/j.ejim.2020.09.024.
[27]	YAO Y, GUO Y T, LIP G Y H，et al. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity：the mAFA-Ⅱ randomized clinical trial[J]. JAMA Netw Open，2021,4(12):e2140071. DOI：10.1001/jamanetworkopen.2021.40071.
[28]	LYTH J, SVENNBERG E, BERNFORT L，et al. Cost-effectiveness of population screening for atrial fibrillation：the STROKESTOP study[J]. Eur Heart J，2023,44(3):196-204. DOI：10.1093/eurheartj/ehac547.
[29]	OGUZ M, LANITIS T, LI X Y，et al. Cost-effectiveness of extended and one-time screening versus no screening for non-valvular atrial fibrillation in the USA[J]. Appl Health Econ Health Policy，2020,18(4):533-545. DOI：10.1007/s40258-019-00542-y.
[30]	CHEN W Y, KHURSHID S, SINGER D E，et al. Cost-effectiveness of screening for atrial fibrillation using wearable devices[J]. JAMA Health Forum，2022,3(8):e222419. DOI：10.1001/jamahealthforum.2022.2419.
[31]	ANDRADE J G, SHAH A, GODIN R，et al. Cost-effectiveness of atrial fibrillation screening in Canadian community practice[J]. Heart Rhythm O2，2023,4(2):103-110. DOI：10.1016/j.hroo.2022.11.003.
[32]	SVENDSEN J H, DIEDERICHSEN S Z, HØJBERG S，et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke （the LOOP Study）：a randomised controlled trial[J]. Lancet，2021,398(10310):1507-1516. DOI：10.1016/S0140-6736(21)01698-6.

可穿戴/移动设备在隐匿性心房颤动管理中的应用进展和挑战

Updated Progress and Challenges in the Application of Wearable/Mobile Devices in the Management of Silent Atrial Fibrillation

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

留言

[1]	中国微循环学会糖尿病与微循环专业委员会, 中华医学会内分泌学分会基层内分泌代谢病学组. 基层糖尿病微血管疾病筛查与防治专家共识（2024）[J]. 中国全科医学, 2024, 27(32): 3969-3986.
[2]	陈凯悦, 李祥龙, 冯钰珩, 励晓红, 郭莺. 糖尿病前期社区健康管理存在的问题及策略建议[J]. 中国全科医学, 2024, 27(28): 3567-3573.
[3]	喻国, 谌金花, 伍悦蕾, 刘述益, 杜文, 肖竹, 王意君. 样本构成的异质性对基层慢性病管理质量调查结果影响的多重对应研究[J]. 中国全科医学, 2024, 27(28): 3515-3519.
[4]	刘长明, 张智, 张勇, 赵茜, 余克林, 薛林美, 苏艳玲, 杨旭东. 国内外儿童整合型健康管理服务模式的概念与框架的研究进展[J]. 中国全科医学, 2024, 27(28): 3574-3580.
[5]	黎婉钰, 张含之, 金花, 于德华. 主动健康导向的基层医疗卫生机构健康管理实施状况研究[J]. 中国全科医学, 2024, 27(28): 3560-3566.
[6]	刘珏, 梁万年. 科技创新应对健康挑战[J]. 中国全科医学, 2024, 27(28): 0-C4.
[7]	何清, 李琳, 王子涵, 代天顾, 张高钰, 樊佳溶, 肖响. 数字疗法在高血压疾病管理中的研究进展[J]. 中国全科医学, 2024, 27(26): 3204-3211.
[8]	王晨瑜, 张晨, 史璐璐, 朱梦娜, 王丽娜. 社区轻度认知障碍人群认知功能健康管理策略的研究进展[J]. 中国全科医学, 2024, 27(26): 3273-3280.
[9]	陈科君, 杨怡菲, 宫静, 杨滨旭, 周静. 电子健康技术在心力衰竭患者居家管理中的应用进展[J]. 中国全科医学, 2024, 27(26): 3212-3217.
[10]	刘添娇, 朴春丽, 赵能江, 李津, 杨叔禹. "三师共管"诊疗模式对不同病程糖尿病患者的临床疗效研究[J]. 中国全科医学, 2024, 27(25): 3121-3128.
[11]	李丽莎, 唐琪, 王草, 吴文辉, 吴欢云, 高振奇, 曹文芳, 吕军. 社区老年人合理用药管理模式对患者用药知信行的影响研究[J]. 中国全科医学, 2024, 27(25): 3129-3135.
[12]	陈永怡, 孟彦辰. 澳大利亚健康医疗数据跨境流动法律规制研究及其对中国的启示[J]. 中国全科医学, 2024, 27(25): 3091-3099.
[13]	苏紫威, 马妍, 周彦彰, 周智梁. 中医药调控线粒体质量控制治疗缺血性卒中的研究进展[J]. 中国全科医学, 2024, 27(24): 3023-3030.
[14]	姜荣生, 张龙, 管其凡, 张静, 吴元丰, 刘明军. 短链脂肪酸在2型糖尿病中的作用研究进展[J]. 中国全科医学, 2024, 27(24): 3031-3037.
[15]	乔慧, 韦艳, 刘玉, 白瑞, 杨萍. 新疆石河子市2019—2021年宫颈癌筛查结果对比分析[J]. 中国全科医学, 2024, 27(23): 2897-2903.